

Argyris Tzouvelekis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2582606/publications.pdf>

Version: 2024-02-01

43
papers

1,448
citations

430874

18
h-index

330143

37
g-index

43
all docs

43
docs citations

43
times ranked

2151
citing authors

#	ARTICLE	IF	CITATIONS
1	Precision medicine in idiopathic pulmonary fibrosis therapy: From translational research to patient-centered care. <i>Current Opinion in Pharmacology</i> , 2021, 57, 71-80.	3.5	7
2	A role of antifibrotics in the treatment of Scleroderma-ILD?. <i>Pulmonology</i> , 2020, 26, 1-2.	2.1	5
3	Endotyping of progressive fibrotic interstitial lung diseases: It is the final destination that matters and not the journey. <i>EBioMedicine</i> , 2020, 51, 102591.	6.1	3
4	Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 60, 101880.	2.6	31
5	Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. <i>ERJ Open Research</i> , 2020, 6, 00152-2020.	2.6	15
6	Hypersensitivity pneumonitis: the first diagnostic guidelines. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 955-957.	10.7	7
7	Shedding light on developmental drugs for idiopathic pulmonary fibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 797-808.	4.1	8
8	Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis. <i>Frontiers in Medicine</i> , 2020, 7, 29.	2.6	18
9	The Role of Hydroxychloroquine in Coronavirus Disease 2019. A Versatile Tool at the Service of Humanity. <i>Frontiers in Medicine</i> , 2020, 7, 176.	2.6	3
10	Autoimmune Biomarkers, Antibodies, and Immunologic Evaluation of the Patient with Fibrotic Lung Disease. <i>Clinics in Chest Medicine</i> , 2019, 40, 679-691.	2.1	7
11	Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 55, 17-24.	2.6	62
12	Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer. <i>Chest</i> , 2019, 156, 383-391.	0.8	84
13	Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?. <i>European Respiratory Journal</i> , 2019, 53, 1800994.	6.7	2
14	Patients with IPF and lung cancer: diagnosis and management. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 86-88.	10.7	67
15	Taking a giant step in the diagnosis of idiopathic pulmonary fibrosis. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 82-84.	10.7	10
16	Pirfenidone in the kaleidoscope: reflecting mechanisms through different angles. <i>European Respiratory Journal</i> , 2018, 52, 1802046.	6.7	8
17	Lung cancer in patients with idiopathic pulmonary fibrosis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 1-10.	2.6	129
18	Diagnostic and prognostic challenges in Idiopathic Pulmonary Fibrosis: A patient's approach. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 42, 21-24.	2.6	18

#	ARTICLE	IF	CITATIONS
19	Dissecting Survival Pathways in Lung Cancer, Fibrosis and Emphysema: "The Four Horses of the Apocalypse" Respiration, 2017, 94, 239-241.	2.6	0
20	Pirfenidone in Idiopathic Pulmonary Fibrosis "RECAP-ulating Safety into the Real World" Respiration, 2017, 94, 405-407.	2.6	4
21	Diagnosis of Idiopathic Pulmonary Fibrosis "Pragmatic Challenges in Clinical Practice" Frontiers in Medicine, 2017, 4, 151.	2.6	14
22	Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis: Thinking Outside the Box in Disease Management and Prognostication. Respiration, 2017, 94, 334-335.	2.6	1
23	A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. Journal of Translational Medicine, 2013, 11, 171.	4.4	209
24	Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema. BMC Pulmonary Medicine, 2013, 13, 31.	2.0	44
25	Anti-acid treatment for idiopathic pulmonary fibrosis. Lancet Respiratory Medicine, the, 2013, 1, 348-349.	10.7	8
26	Stem Cell Treatment for Chronic Lung Diseases. Respiration, 2013, 85, 179-192.	2.6	35
27	Increased Expression of Epidermal Growth Factor Receptor (EGF-R) in Patients with Different Forms of Lung Fibrosis. BioMed Research International, 2013, 2013, 1-11.	1.9	43
28	Stem Cell Therapy in Chronic Obstructive Pulmonary Disease. Seeking the Prometheus Effect. Current Drug Targets, 2013, 14, 246-252.	2.1	14
29	Embryonic stem cells for lung fibrosis Is it the Prometheus myth or the Pandora's Box?. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2013, 30, 246-8.	0.2	0
30	Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis. Pulmonary Medicine, 2012, 2012, 1-7.	1.9	56
31	Idiopathic Pulmonary Hemosiderosis in Adults: A Case Report and Review of the Literature. Case Reports in Medicine, 2012, 2012, 1-5.	0.7	14
32	Expression of Hypoxia-Inducible Factor (HIF)-1 α -Vascular Endothelial Growth Factor (VEGF)-Inhibitory Growth Factor (iNG)-4 axis in sarcoidosis patients. BMC Research Notes, 2012, 5, 654.	1.4	26
33	Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis. Pulmonary Medicine, 2011, 2011, 1-7.	1.9	11
34	Stem cell therapy in pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2011, 17, 368-373.	2.6	49
35	Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. Journal of Translational Medicine, 2011, 9, 182.	4.4	61
36	Down-regulation of the inhibitor of growth family member 4 (iNG4) in different forms of pulmonary fibrosis. Respiratory Research, 2009, 10, 14.	3.6	15

#	ARTICLE	IF	CITATIONS
37	Acute fibrinous and organising pneumonia: a case report and review of the literature. Journal of Medical Case Reports, 2009, 3, 74.	0.8	27
38	Post-intubation pulmonary embolism and tracheal stenosis: A case report and review of the literature. Respiratory Medicine, 2008, 102, 1208-1212.	2.9	1
39	Comparative Expression Profiling in Pulmonary Fibrosis Suggests a Role of Hypoxia-inducible Factor-1 α in Disease Pathogenesis. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1108-1119.	5.6	178
40	Angiogenesis in Interstitial Lung Diseases: a pathogenetic hallmark or a bystander?. Respiratory Research, 2006, 7, 82.	3.6	42
41	Serum biomarkers in Acute Respiratory Distress Syndrome an ailing prognosticator. Respiratory Research, 2005, 6, 62.	3.6	28
42	Serum biomarkers in interstitial lung diseases. Respiratory Research, 2005, 6, 78.	3.6	69
43	Application of microarray technology in pulmonary diseases. Respiratory Research, 2004, 5, 26.	3.6	15